Cited by 32Bone fractures and treatmentsBone health and osteoporosis researchBone Tissue Engineering Materials

Investigational drugs for fracture healing: preclinical & clinical data

E. Klontzas, Michail, I. Kenanidis, Eustathios, J. MacFarlane, Robert, Michail, Theodoros, E. Potoupnis, Michael, Heliotis, Manolis, Mantalaris, Athanasios, Tsiridis, Eleftherios·2016·Expert Opinion on Investigational Drugs

Abstract

INTRODUCTION: The need for fracture healing enhancement for the management of fracture complications such as non-union and for the achievement of early function in fracture patients is constantly increasing. Therefore, the development and evaluation of novel pharmaceutical agents is mandatory in order to accelerate the process and increase bone union rates. AREAS COVERED: This review summarizes the most recent knowledge on the pharmacological enhancement of fracture repair. It provides a synopsis of the most important preclinical and clinical studies published over the past five years on long bone fracture healing. EXPERT OPINION: To date, limited drugs seem to have the potential for clinical use in fracture healing enhancement and the field is progressing very slowly. Among anti-osteoporotic drugs, only PTH and anti-sclerostin antibodies have such a potential but further research is needed before clinical use. The same applies also to BMPs, the use of which still carries major drawbacks that should be overcome before their widespread clinical utilization. Other drugs and growth factors, such as statins, VEGF, FGF, EPO, could be future key players in fracture healing but evidence is still lacking. Further in depth understanding of the healing process is essential in order to identify novel effective pharmacological agents.

Integrity signals

Registry

Crossref · 10.1517/13543784.2016.1161757

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is a lack of evidence from clinical studies in patients for selective prostaglandin agonists, cyasterone, statins, and anti-sclerostin antibodies as fracture-healing accelerators.

    “Other drugs that have been considered to accelerate fracture healing include selective prostaglandin agonists (111), cyasterone (112), statins, and anti-sclerostin antibodies (113), but there is a lack of evidence from clinical studies in patients.”

Cites

3 retracted

Flagged first, then by citations

Cited by

Authors
E. Klontzas, M., I. Kenanidis, E., J. MacFarlane, R., Michail, T., E. Potoupnis, M., Heliotis, M., Mantalaris, A., & Tsiridis, E.
Affiliations
  • Aristotle University of Thessaloniki (GR)
  • London North West Healthcare NHS Trust (GB)
  • Imperial College London (GB)
Corresponding author
Tsiridis, Eleftherios
Venue
Expert Opinion on Investigational Drugs
Published
2016-03-28
Volume
25
Issue
5
Pages
585-596
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2326833633
Cited by
32
References
126
Citations by year
2024: 3 · 2023: 1 · 2022: 7 · 2021: 4 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 1
FWCI
0.72
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Bone fractures and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
Keywords
fracture healing, nonunion, long bone fractures, parathyroid hormone, anti-sclerostin antibody, bone morphogenetic proteins, growth factors, statins, vascular endothelial growth factor, fibroblast growth factor, erythropoietin, osteoporosis drugs, pharmacological agents
MeSH terms
Animals, Humans, Osteoporosis, Drugs, Investigational, Fracture Healing, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Bone Morphogenetic Proteins, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review